Voyager Therapeutics’ (VYGR) “Overweight” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for Voyager Therapeutics’ FY2025 earnings at ($2.03) EPS. Several other analysts have also recently weighed in on VYGR. StockNews.com cut shares of Voyager Therapeutics from a […]
Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for Voyager Therapeutics’ FY2025 earnings at ($2.03) EPS. Several other analysts have also recently weighed in on VYGR. StockNews.com cut shares of Voyager Therapeutics from a […]
